Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

20111,879 citationsJournal Articlebronze Open Access

Authors

Jessica L. Mega · Brigham and Women's Hospital

Eugene Braunwald · Brigham and Women's Hospital

Stephen D. Wiviott · Harvard University

Jean‐Pierre Bassand · Centre Hospitalier Universitaire de Besançon

Deepak L. Bhatt · Brigham and Women's Hospital

Christoph Bode · University Medical Center Freiburg

Paul Burton

Abstract

In patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke. Rivaroxaban increased the risk of major bleeding and intracranial hemorrhage but not the risk of fatal bleeding. (Funded by Johnson & Johnson and Bayer Healthcare; ATLAS ACS 2-TIMI 51 ClinicalTrials.gov number, NCT00809965.).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Antiplatelet Therapy and Cardiovascular Diseases Venous Thromboembolism Diagnosis and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 1, pp. 9-19

DOI: 10.1056/nejmoa1112277

Field-Weighted Citation Impact: 110.40